01:15 PM EDT, 07/25/2024 (MT Newswires) -- Actinium Pharmaceuticals ( ATNM ) said Thursday that the FDA has approved the biotech firm's investigational new-drug application to study Iomab-ACT to treat patients with sickle cell disease.

This trial, which will be conducted with Columbia University, will evaluate the safety of Iomab-ACT in patients with sickle cell disease receiving an allogeneic bone marrow transplant, according to Actinium Pharmaceuticals ( ATNM ).

The company said that if the study is successful it expects it to inform a clinical trial to evaluate Iomab-ACT as a targeted conditioning agent prior to gene therapy.

Shares of Actinium Pharmaceuticals ( ATNM ) were up 3.3% in recent trading.

Price: 8.00, Change: +0.26, Percent Change: +3.29